436 related articles for article (PubMed ID: 31792640)
21. Clinical efficacy and safety of topiroxostat in Japanese hyperuricemic patients with or without gout: a randomized, double-blinded, controlled phase 2b study.
Hosoya T; Sasaki T; Ohashi T
Clin Rheumatol; 2017 Mar; 36(3):649-656. PubMed ID: 27832384
[TBL] [Abstract][Full Text] [Related]
22. Dotinurad: a clinical pharmacokinetic study of a novel, selective urate reabsorption inhibitor in subjects with hepatic impairment.
Kumagai Y; Sakaki M; Furihata K; Ito T; Inoue K; Yoshida T; Matsumoto S; Furuno K; Hagino A
Clin Exp Nephrol; 2020 Mar; 24(Suppl 1):25-35. PubMed ID: 31760530
[TBL] [Abstract][Full Text] [Related]
23. Placebo-controlled double-blind dose-response study of the non-purine-selective xanthine oxidase inhibitor febuxostat (TMX-67) in patients with hyperuricemia (including gout patients) in japan: late phase 2 clinical study.
Kamatani N; Fujimori S; Hada T; Hosoya T; Kohri K; Nakamura T; Ueda T; Yamamoto T; Yamanaka H; Matsuzawa Y
J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S35-43. PubMed ID: 21654268
[TBL] [Abstract][Full Text] [Related]
24. Verinurad combined with febuxostat in Japanese adults with gout or asymptomatic hyperuricaemia: a phase 2a, open-label study.
Shiramoto M; Liu S; Shen Z; Yan X; Yamamoto A; Gillen M; Ito Y; Hall J
Rheumatology (Oxford); 2018 Sep; 57(9):1602-1610. PubMed ID: 29868853
[TBL] [Abstract][Full Text] [Related]
25. Safety and efficacy of verinurad, a selective URAT1 inhibitor, for the treatment of patients with gout and/or asymptomatic hyperuricemia in the United States and Japan: Findings from two phase II trials.
Fitz-Patrick D; Roberson K; Niwa K; Fujimura T; Mori K; Hall J; Yan X; Shen Z; Liu S; Ito Y; Baumgartner S
Mod Rheumatol; 2019 Nov; 29(6):1042-1052. PubMed ID: 30334639
[No Abstract] [Full Text] [Related]
26. Discovery and characterization of verinurad, a potent and specific inhibitor of URAT1 for the treatment of hyperuricemia and gout.
Tan PK; Liu S; Gunic E; Miner JN
Sci Rep; 2017 Apr; 7(1):665. PubMed ID: 28386072
[TBL] [Abstract][Full Text] [Related]
27. Clinical pharmacological study of dotinurad administered to male and female elderly or young subjects.
Nakatani H; Fushimi M; Sasaki T; Okui D; Ohashi T
Clin Exp Nephrol; 2020 Mar; 24(Suppl 1):8-16. PubMed ID: 31889230
[TBL] [Abstract][Full Text] [Related]
28. Stronger Uricosuric Effects of the Novel Selective URAT1 Inhibitor UR-1102 Lowered Plasma Urate in Tufted Capuchin Monkeys to a Greater Extent than Benzbromarone.
Ahn SO; Ohtomo S; Kiyokawa J; Nakagawa T; Yamane M; Lee KJ; Kim KH; Kim BH; Tanaka J; Kawabe Y; Horiba N
J Pharmacol Exp Ther; 2016 Apr; 357(1):157-66. PubMed ID: 26907620
[TBL] [Abstract][Full Text] [Related]
29. [Pharmacological properties and clinical efficacy of dotinurad (URECE
Taniguchi T; Ashizawa N
Nihon Yakurigaku Zasshi; 2020; 155(6):426-434. PubMed ID: 33132262
[TBL] [Abstract][Full Text] [Related]
30. Unique Binding Sites of Uricosuric Agent Dotinurad for Selective Inhibition of Renal Uric Acid Reabsorptive Transporter URAT1.
Fujita K; Isozumi N; Zhu Q; Matsubayashi M; Taniguchi T; Arakawa H; Shirasaka Y; Mori E; Tamai I
J Pharmacol Exp Ther; 2024 Jun; 390(1):99-107. PubMed ID: 38670801
[TBL] [Abstract][Full Text] [Related]
31. [Uricosuric agent].
Ohno I
Nihon Rinsho; 2008 Apr; 66(4):743-7. PubMed ID: 18409525
[TBL] [Abstract][Full Text] [Related]
32. Changes in Urinary Uric Acid Concentration after Dotinurad Administration to Patients with Hyperuricemia: A Post Hoc Analysis of Two Clinical Trials in Japan.
Takahashi T; Sasaki M; Shimizu T; Yamaguchi S
Clin Pharmacol Drug Dev; 2024 Jan; 13(1):87-95. PubMed ID: 37559414
[TBL] [Abstract][Full Text] [Related]
33. A Possible Therapeutic Application of the Selective Inhibitor of Urate Transporter 1, Dotinurad, for Metabolic Syndrome, Chronic Kidney Disease, and Cardiovascular Disease.
Yanai H; Adachi H; Hakoshima M; Iida S; Katsuyama H
Cells; 2024 Mar; 13(5):. PubMed ID: 38474414
[TBL] [Abstract][Full Text] [Related]
34. URC102, a potent and selective inhibitor of hURAT1, reduced serum uric acid in healthy volunteers.
Lee HA; Yu KS; Park SI; Yoon S; Onohara M; Ahn Y; Lee H
Rheumatology (Oxford); 2019 Nov; 58(11):1976-1984. PubMed ID: 31056705
[TBL] [Abstract][Full Text] [Related]
35. Placebo-controlled, double-blind study of the non-purine-selective xanthine oxidase inhibitor Febuxostat (TMX-67) in patients with hyperuricemia including those with gout in Japan: phase 3 clinical study.
Kamatani N; Fujimori S; Hada T; Hosoya T; Kohri K; Nakamura T; Ueda T; Yamamoto T; Yamanaka H; Matsuzawa Y
J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S19-26. PubMed ID: 21654266
[TBL] [Abstract][Full Text] [Related]
36. Overview of the pharmacokinetics and pharmacodynamics of URAT1 inhibitors for the treatment of hyperuricemia and gout.
Hou Z; Ma A; Mao J; Song D; Zhao X
Expert Opin Drug Metab Toxicol; 2023 Dec; 19(12):895-909. PubMed ID: 37994776
[TBL] [Abstract][Full Text] [Related]
37. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.
Schumacher HR; Becker MA; Wortmann RL; Macdonald PA; Hunt B; Streit J; Lademacher C; Joseph-Ridge N
Arthritis Rheum; 2008 Nov; 59(11):1540-8. PubMed ID: 18975369
[TBL] [Abstract][Full Text] [Related]
38. Lesinurad: A Review in Hyperuricaemia of Gout.
Deeks ED
Drugs Aging; 2017 May; 34(5):401-410. PubMed ID: 28425024
[TBL] [Abstract][Full Text] [Related]
39. Serum Urate-Lowering Efficacy and Safety of Tigulixostat in Gout Patients With Hyperuricemia: A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Trial.
Terkeltaub R; Lee J; Min J; Shin S; Saag KG
Arthritis Rheumatol; 2023 Jul; 75(7):1275-1284. PubMed ID: 36649008
[TBL] [Abstract][Full Text] [Related]
40. Comparative efficacy and safety of dotinurad, febuxostat, and benzbromarone in hyperuricemic patients with or without gout: A network meta-analysis of randomized controlled trials.
Lee YH; Song GG
Int J Clin Pharmacol Ther; 2022 Mar; 60(3):159-166. PubMed ID: 34779393
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
